Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2013

Open Access 01-10-2013 | Research article

Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development

Authors: Christiane Danilo, Jorge L Gutierrez-Pajares, Maria Antonietta Mainieri, Isabelle Mercier, Michael P Lisanti, Philippe G Frank

Published in: Breast Cancer Research | Issue 5/2013

Login to get access

Abstract

Introduction

Previous studies have identified cholesterol as an important regulator of breast cancer development. High-density lipoprotein (HDL) and its cellular receptor, the scavenger receptor class B type I (SR-BI) have both been implicated in the regulation of cellular cholesterol homeostasis, but their functions in cancer remain to be established.

Methods

In the present study, we have examined the role of HDL and SR-BI in the regulation of cellular signaling pathways in breast cancer cell lines and in the development of tumor in a mouse xenograft model.

Results

Our data show that HDL is capable of stimulating migration and can activate signal transduction pathways in the two human breast cancer cell lines, MDA-MB-231 and MCF7. Furthermore, we also show that knockdown of the HDL receptor, SR-BI, attenuates HDL-induced activation of the phosphatidylinositol 3-kinase (PI3K)/protein Kinase B (Akt) pathway in both cell lines. Additional investigations show that inhibition of the PI3K pathway, but not that of the mitogen-activated protein kinase (MAPK) pathway, could lead to a reduction in cellular proliferation in the absence of SR-BI. Importantly, whereas the knockdown of SR-BI led to decreased proliferation and migration in vitro, it also led to a significant reduction in tumor growth in vivo. Most important, we also show that pharmacological inhibition of SR-BI can attenuate signaling and lead to decreased cellular proliferation in vitro. Taken together, our data indicate that both cholesteryl ester entry via HDL-SR-BI and Akt signaling play an essential role in the regulation of cellular proliferation and migration, and, eventually, tumor growth.

Conclusions

These results identify SR-BI as a potential target for the treatment of breast cancer.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H: Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med. 2000, 6: 307-311.PubMed
3.
Potischman N, McCulloch CE, Byers T, Houghton L, Nemoto T, Graham S, Campbell TC: Associations between breast cancer, plasma triglycerides, and cholesterol. Nutr Cancer. 1991, 15: 205-215. 10.1080/01635589109514128.CrossRefPubMed
4.
Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I: Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004, 96: 1152-1160. 10.1093/jnci/djh216.CrossRefPubMed
5.
Ray G, Husain SA: Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 2001, 34: 71-76. 10.1016/S0009-9120(00)00200-9.CrossRefPubMed
6.
Kritchevsky SB, Kritchevsky D: Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr. 1992, 12: 391-416. 10.1146/annurev.nu.12.070192.002135.CrossRefPubMed
7.
Boyd NF, McGuire V: Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst. 1990, 82: 460-468. 10.1093/jnci/82.6.460.CrossRefPubMed
8.
Ferraroni M, Gerber M, Decarli A, Richardson S, Marubini E, Crastes de Paulet P, Crastes de Paulet A, Pujol H: HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol. 1993, 22: 772-780. 10.1093/ije/22.5.772.CrossRefPubMed
9.
Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM: Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011, 29: 1592-1598. 10.1200/JCO.2010.31.5200.CrossRefPubMedPubMedCentral
10.
Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, Leroith D: Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 2012, 8: 961-967.
11.
Jozan S, Faye JC, Tournier JF, Tauber JP, David JF, Bayard F: Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditions. Biochem Biophys Res Commun. 1985, 133: 105-112. 10.1016/0006-291X(85)91847-9.CrossRefPubMed
12.
Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG: Role of cholesterol in the development and progression of breast cancer. Am J Pathol. 2011, 178: 402-412. 10.1016/j.ajpath.2010.11.005.CrossRefPubMedPubMedCentral
13.
Pan B, Ren H, Lv X, Zhao Y, Yu B, He Y, Ma Y, Niu C, Kong J, Yu F, Sun WB, Zhang Y, Willard B, Zheng L: Hypochlorite-induced oxidative stress elevates the capability of HDL in promoting breast cancer metastasis. J Transl Med. 2012, 10: 65-10.1186/1479-5876-10-65.CrossRefPubMedPubMedCentral
14.
Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, Pan L, Li J, Yang L, Lv X, et al: High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2011, 131: 70-82.CrossRefPubMed
15.
Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, Sattler W: The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. Biochem J. 2000, 349: 559-566. 10.1042/0264-6021:3490559.CrossRefPubMedPubMedCentral
16.
Rotheneder M, Kostner GM: Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer. 1989, 43: 875-879. 10.1002/ijc.2910430523.CrossRefPubMed
17.
Pan B, Ren H, He Y, Lv X, Ma Y, Li J, Huang L, Yu B, Kong J, Niu C, et al: HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res. 2012, 18: 1246-1256. 10.1158/1078-0432.CCR-11-0817.CrossRefPubMed
18.
19.
Staubach S, Hanisch FG: Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics. 2011, 8: 263-277. 10.1586/epr.11.2.CrossRefPubMed
20.
Coleman PS, Chen L-C, Sepp-Lorenzino L: Cholesterol metabolism and tumor cell proliferation. Subcellular Biochemistry, Volume 28. Edited by: Bittman R. 1997, New York: Plenum Press, 363-435.
21.
Danilo C, Frank PG: Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012, 12: 677-682. 10.1016/j.coph.2012.07.009.CrossRefPubMed
22.
Grewal T, de Diego I, Kirchhoff MF, Tebar F, Heeren J, Rinninger F, Enrich C: High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem. 2003, 278: 16478-16481. 10.1074/jbc.C300085200.CrossRefPubMed
23.
Mineo C, Yuhanna IS, Quon MJ, Shaul PW: High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003, 278: 9142-9149. 10.1074/jbc.M211394200.CrossRefPubMed
24.
Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, Hahner LD, Cummings ML, Kitchens RL, Marcel YL, et al: High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006, 98: 63-72.CrossRefPubMed
25.
Al-Jarallah A, Trigatti BL: A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways. Biochim Biophys Acta. 2010, 1801: 1239-1248. 10.1016/j.bbalip.2010.08.006.CrossRefPubMed
26.
Assanasen C, Mineo C, Seetharam D, Yuhanna IS, Marcel YL, Connelly MA, Williams DL, de la Llera-Moya M, Shaul PW, Silver DL: Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest. 2005, 115: 969-977.CrossRefPubMedPubMedCentral
27.
Saddar S, Mineo C, Shaul PW: Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol. 2009, 30: 144-150.CrossRef
28.
Krieger M: Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999, 68: 523-558. 10.1146/annurev.biochem.68.1.523.CrossRefPubMed
29.
Twiddy AL, Cox ME, Wasan KM: Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate. 2012, 72: 955-965. 10.1002/pros.21499.CrossRefPubMed
30.
Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NC, Ishida T: A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004, 64: 1515-1521. 10.1158/0008-5472.CAN-03-0675.CrossRefPubMed
31.
Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, et al: Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010, 9: 3506-3514. 10.4161/cc.9.17.12731.CrossRefPubMedPubMedCentral
32.
Redgrave TG, Roberts DC, West CE: Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975, 65: 42-49. 10.1016/0003-2697(75)90488-1.CrossRefPubMed
33.
Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, et al: Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol. 2006, 169: 1784-1801. 10.2353/ajpath.2006.060590.CrossRefPubMedPubMedCentral
34.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: Opinion: migrating cancer stem cells: an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005, 5: 744-749.CrossRefPubMed
35.
Sekine Y, Suzuki K, Remaley AT: HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion. Prostate. 2011, 71: 690-699. 10.1002/pros.21285.CrossRefPubMed
36.
Kellner-Weibel G, de La Llera-Moya M, Connelly MA, Stoudt G, Christian AE, Haynes MP, Williams DL, Rothblat GH: Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry. 2000, 39: 221-229. 10.1021/bi991666c.CrossRefPubMed
37.
Nieland TJ, Penman M, Dori L, Krieger M, Kirchhausen T: Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A. 2002, 99: 15422-15427. 10.1073/pnas.222421399.CrossRefPubMedPubMedCentral
38.
Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, Schaffner CP, Kim J, Freeman MR: Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol. 2009, 174: 1017-1026. 10.2353/ajpath.2009.080551.CrossRefPubMedPubMedCentral
39.
Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005, 94: 29-86.CrossRefPubMed
40.
Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005, 96: 1221-1232. 10.1161/01.RES.0000170946.56981.5c.CrossRefPubMed
41.
Terasaka N, Wang N, Yvan-Charvet L, Tall AR: High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci U S A. 2007, 104: 15093-15098. 10.1073/pnas.0704602104.CrossRefPubMedPubMedCentral
42.
Deeg MA, Bowen RF, Oram JF, Bierman EL: High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Arterioscler Thromb Vasc Biol. 1997, 17: 1667-1674. 10.1161/01.ATV.17.9.1667.CrossRefPubMed
43.
Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K, Remaley AT: High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res. 2010, 8: 1284-1294. 10.1158/1541-7786.MCR-10-0008.CrossRefPubMedPubMedCentral
44.
Whyte J, Bergin O, Bianchi A, McNally S, Martin F: Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 2009, 11: 209-10.1186/bcr2361.CrossRefPubMedPubMedCentral
45.
Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501. 10.1038/nrc839.CrossRefPubMed
46.
Murugesan G, Sa G, Fox PL: High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ Res. 1994, 74: 1149-1156. 10.1161/01.RES.74.6.1149.CrossRefPubMed
47.
Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005, 115: 959-968.CrossRefPubMedPubMedCentral
48.
49.
Zannis VI, Chroni A, Krieger M: Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006, 84: 276-294. 10.1007/s00109-005-0030-4.CrossRefPubMed
50.
Paillasse MR, de Medina P, Amouroux G, Mhamdi L, Poirot M, Silvente-Poirot S: Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J Lipid Res. 2009, 50: 2203-2211. 10.1194/jlr.M800668-JLR200.CrossRefPubMedPubMedCentral
51.
de Medina P, Boubekeur N, Balaguer P, Favre G, Silvente-Poirot S, Poirot M: The prototypical inhibitor of cholesterol esterification, Sah 58–035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors. J Pharmacol Exp Ther. 2006, 319: 139-149. 10.1124/jpet.106.104349.CrossRefPubMed
52.
de Medina P, Genovese S, Paillasse MR, Mazaheri M, Caze-Subra S, Bystricky K, Curini M, Silvente-Poirot S, Epifano F, Poirot M: Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors. Mol Pharmacol. 2010, 78: 827-836. 10.1124/mol.110.065250.CrossRefPubMed
Metadata
Title
Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development
Authors
Christiane Danilo
Jorge L Gutierrez-Pajares
Maria Antonietta Mainieri
Isabelle Mercier
Michael P Lisanti
Philippe G Frank
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3483

Other articles of this Issue 5/2013

Breast Cancer Research 5/2013 Go to the issue

Viewpoint

Top Notch cancer stem cells by paracrine NF-κB signaling in breast cancer

Editorial

Decision aids for breast cancer chemoprevention

Research article

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models

Meeting report

‘The charmingest place’: non-coding RNA, lineage tracing, tumor heterogeneity, metastasis and metabolism - new methods in mammary gland development and cancer: the fifth ENBDC Workshop

Research article

Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

Research article

Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits